ANI Pharma Reports Strong Q3 2026 Results Driven by Rare Disease Segment Growth
ANI Pharma (ANIP) reported robust third-quarter 2026 financial results, highlighted by a 28% year-over-year increase in total net revenue to $290.8 million. The company's strategic pivot toward the rare disease sector yielded significant results, with rare disease net revenue climbing 36% to $160.9 million. This growth was largely propelled by Purified Cortrophin Gel, which saw a 36% increase in revenue due to volume expansion and its new gout indication. Despite strong top-line performance and record operating cash flow of $83.8 million, the company adjusted its full-year guidance for Cortrophin Gel downward due to specialty pharmacy capacity constraints and slower patient conversion rates. However, management raised its full-year Adjusted EBITDA and Non-GAAP EPS guidance, reflecting overall improved profitability. The company also highlighted its progress in inorganic growth through a $560 million acquisition offer for Egetis Therapeutics.
Topics: financial performance generics rare disease revenue growth